1. Scrip

Billions On The Line With Celgene’s Partnered Pipeline

 
• By Mandy Jackson

Celgene’s fourth quarter and 2016 sales aligned with previously disclosed double-digit gains as the company outlined later-stage pipeline programs expected to add billions in sales during the next five years.

Celgene Corp. had another double-digit growth year and expects sales spikes to continue for the next several years. Driving that view is existing blockbusters as well as mid- to late-stage research and development programs, many of which the company highlighted in its Jan. 26 earnings report.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.